The Cardiovascular Risk of GH-Deficient Adolescents
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
To investigate the onset of the cardiovascular impairment in patients with GH deficiency (GHD), we prospectively studied cardiovascular risk parameters, cardiac mass and performance (by echocardiography) in 10 adolescent patients (5 with isolated GHD and 5 with multiple GHD) who reached their final height before GH replacement withdrawal, 6 months after GH replacement withdrawal, and 6 months after GH treatment was restarted, and in 10 sex- and age-matched controls. At study entry, when compared with controls, GHD adolescents had lower IGF-I levels (although still in the normal age range) and high-density lipoprotein (HDL)-cholesterol levels, higher total/HDL-cholesterol ratio, lower triglyceride levels, higher fibrinogen levels, and lower heart rate, systolic blood pressure, and early-to-late mitral flow velocity ratio (E/A). Left ventricular (LV) mass index and ejection fraction were normal. Six months after GH withdrawal, IGF-I levels decreased remarkably in all cases (from 176.6 +/- 8.3 to 77.5 +/- 8.9 microg/liter; P < 0.001), whereas low-density lipoprotein-cholesterol and triglyceride levels significantly increased. The total/HDL-cholesterol ratio (from 3.89 +/- 0.1 to 4.74 +/- 0.2; P < 0.05) and fibrinogen levels (from 261 +/- 7.1 to 287.5 +/- 6.4 mg/dl; P < 0.05) also significantly increased compared with study entry, without any change in the other parameters. In contrast, both LV mass index (from 94.2 +/- 1.6 to 87.8 +/- 1.7 g/m(2); P = 0.05) and E/A (from 1.32 +/- 0.05 to 1.12 +/- 0.03; P < 0.01) decreased, although remaining in the normal range. Six months after restarting GH replacement (at a median dose of 10 micro g/kg x d), lipid and cardiac parameters were brought back to the levels measured at study entry, but in no patient did IGF-I levels reach the 50th centile for age. HDL-cholesterol levels (P < 0.0001), heart rate (P < 0.05), systolic blood pressure (P < 0.01), LV ejection fraction (P < 0.005), and E/A (P < 0.0001) remained lower, whereas total/HDL-cholesterol ratio (P < 0.01), triglycerides, and fibrinogen levels (P < 0.05) remained higher than controls. In conclusion, GH discontinuation is inappropriate in adolescents with severe GHD, inducing impairment of lipid profile and cardiac morphology and performance. Because the results on the cardiovascular system and on the lipid profile were suboptimal, it is likely that the GH dose in severe GHD adolescents should be higher.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006
Increased cerebrovascular mortality in patients with hypopituitarism
Bülow, B., Hagmar, L., Mikoczy, Z., Nordström, C., & Erfurth, E. M. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.d01-1749.x · Cited by 542
The effect of hypopituitarism on life expectancy.
Bates, A. S., Van't Hoff, W., Jones, P. J., & Clayton, R. N. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.3.8772595 · Cited by 475
Cited by
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Bernardo, B. C., Weeks, K. L., Pretorius, L., & McMullen, J. R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.005 · Cited by 894
Estrogen Regulation of Growth Hormone Action
Leung, K.-C., Johannsson, G., Leong, G. M., & Ho, K. K. Y. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0035 · Cited by 542
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., Shalet, S. M., Vance, M. L., & for The Endocrine Society’s Clinical Guidelines Subcommittee (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2227 · Cited by 424
Gurney, J. G., Ness, K. K., Sibley, S. D., O'Leary, M., Dengel, D. R., Lee, J. M., Youngren, N. M., Glasser, S. P., & Baker, K. S. (2006) · Cancer · doi:10.1002/cncr.22120 · Cited by 312
Metadata
- Authors
- Colao, A.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-08-01
- Volume
- 87
- Issue
- 8
- Pages
- 3650-3655
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2125772408
- Cited by
- 116
- References
- 4
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Cardiovascular Risk of GH-Deficient Adolescents. https://app.cochat.ai/papers/10.1210/jc.87.8.3650
- The paper
- Colao, A. (2002). The Cardiovascular Risk of GH-Deficient Adolescents. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.87.8.3650
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.